BreezeBio Raises $60 Million to Develop mRNA-Based Diabetes Therapy

The Science of Pancreatic Targeting

Targeting the pancreas has been one of the most difficult challenges in drug delivery. The organ is located deep in the abdomen, behind the stomach, and receives only a small fraction of cardiac output — meaning that systemically administered drugs are diluted before they arrive. The pancreatic islets, which make up only about 1-2 percent of the organ's mass, are even harder to reach selectively.

BreezeBio's approach involves engineering nanoparticles with surface ligands — molecular hooks — that bind to receptors specifically expressed on islet cells. This active targeting strategy, combined with the particles' optimized size for crossing the pancreatic vasculature, is designed to concentrate the mRNA payload where it is needed while minimizing off-target delivery to the liver and other organs.

The company has published preclinical data showing that its polymer nanoparticles can deliver mRNA to pancreatic islet cells in animal models with efficiency several-fold higher than conventional LNPs. The translated protein was detected in islet cells at levels sufficient to produce a measurable physiological effect — a critical proof of concept that the delivery system works in a living organism.

mRNA Beyond Vaccines

BreezeBio's work is part of a broader effort to extend the mRNA platform beyond infectious disease vaccines into therapeutic applications. Since the success of the Pfizer-BioNTech and Moderna COVID-19 vaccines demonstrated that mRNA could be safely administered to billions of people, researchers have been racing to apply the technology to cancer immunotherapy, rare genetic diseases, autoimmune conditions, and now metabolic disorders like diabetes.

The appeal of mRNA as a therapeutic modality is that it is inherently programmable. Once a delivery system is developed, the mRNA payload can be swapped to encode virtually any protein, making the same platform applicable to many different diseases. This modularity accelerates development timelines and reduces costs compared to traditional biologics, which must be manufactured as finished proteins.

For diabetes specifically, several mRNA-based approaches are being explored. Some aim to deliver mRNA encoding insulin directly, providing a long-acting alternative to injections. Others, like BreezeBio's, target upstream biology — reprogramming cells to restore normal insulin production or sensitivity. Still others are using mRNA to express immune-modulating proteins that could prevent the autoimmune destruction of beta cells in Type 1 diabetes.

The Road to the Clinic

Despite the scientific promise, mRNA therapeutics for chronic diseases face challenges that vaccines do not. A vaccine requires only one or two doses to prime the immune system, while a therapy for diabetes would likely require repeated administration over a patient's lifetime. This raises questions about long-term safety, immunogenicity — the body's tendency to mount an immune response against the delivery vehicle itself — and the practicality of the dosing regimen.

BreezeBio has indicated that its polymer nanoparticles are designed to minimize immunogenicity through careful selection of biocompatible and biodegradable polymers. The company is also exploring sustained-release formulations that could reduce dosing frequency, potentially to monthly or even quarterly injections — a significant improvement over the daily or weekly insulin regimens that many patients currently endure.

The $60 million in funding gives BreezeBio a runway to advance its lead program through the remaining preclinical studies needed to file an investigational new drug application and begin first-in-human clinical trials. If the data hold up, the company could be testing its mRNA diabetes therapy in patients within the next two to three years.

For the diabetes community — patients, clinicians, and payers alike — the prospect of a treatment that goes beyond blood sugar management to address the root causes of the disease is both tantalizing and long overdue. BreezeBio's polymer nanoparticle platform represents one of several promising paths toward that goal, and the investment suggests that the scientific and business case is compelling enough to bet on.

This article is based on reporting by endpoints.news. Read the original article.